Can Bcl-XL expression predict the radio sensitivity of bilharzial-related squamous bladder carcinoma?
Adjuvant radiotherapy for muscle invasive bilharzial related squamous cell carcinoma of the urinary bladder has potential effectiveness and minor side effects. Moreover, Bcl-XL expression is a valuable tool for predicting those who might not respond to this adjuvant treatment.
The results suggests that miR-224 might serve as a predictor for paclitaxel response or a therapeutic target in cervical cancer therapy.